Drug Type Bispecific antibody |
Synonyms GO 14C9, GO-14C9 |
Target- |
Action modulators |
Mechanism Immunomodulators |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Esophageal Carcinoma | Preclinical | United States | 01 Nov 2021 | |
Liver Cancer | Preclinical | United States | 01 Nov 2021 | |
Stomach Cancer | Preclinical | United States | 01 Nov 2021 |